Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.
One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419…
Arianna10.06.2022